Chemoprevention of Patients with Hepatitis B Receiving Chemotherapy or Bone Marrow Transplant
| Autor: | Kavitha Gopal, Albert D. Min |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Hepatitis B virus
Hepatology business.industry medicine.medical_treatment virus diseases Immunosuppression Hepatitis B medicine.disease_cause medicine.disease digestive system diseases Transplantation Pharmacotherapy Virology Immunology Chemoprophylaxis medicine Fulminant hepatitis Viral hepatitis business |
| Zdroj: | Current Hepatitis Reports. 9:178-186 |
| ISSN: | 1541-0706 1540-3416 |
| DOI: | 10.1007/s11901-010-0048-0 |
| Popis: | Hepatitis B virus (HBV) reactivation is a common but preventable complication of immunosuppression. With the advent of new therapies that provide efficient and prolonged immunosuppression, the incidence of HBV reactivation is likely to increase. The clinical presentation can range from mildly elevated aminotransferase values to fatal fulminant hepatitis. Despite prompt antiviral therapy, the mortality rates remain high, and it can adversely affect the outcome of immunosuppressive therapy for the underlying hematological disease. Over the past decade, several studies evaluated the risk of HBV reactivation, role of serological tests, and effectiveness of antiviral therapies in preventing severe hepatic dysfunction among patients undergoing immunosuppressive therapy. Studies show that HBV antiviral therapy given prior to chemotherapy may prevent HBV replication, and reduce the risk of HBV reactivation during the immunosuppression period. This article reviews the current literature and society guidelines on HBV reactivation, risk factors, and prophylaxis for HBV reactivation in patients undergoing chemo-/immunosuppressive therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|